The wrong prescription for drug affordability

The Medication Affordability and Patent Integrity Act aims to tackle drug pricing but, critics argue, it will instead complicate the development of new medications by imposing excessive regulatory hurdles on biotech firms. This could slow innovation and delay the introduction of life-saving therapies without addressing the underlying issues driving high prescription prices. Essentially, it places a heavy burden on the very sector that's crucial for advancing medical science and could end up costing taxpayers more in the long run due to less competitive drug markets.